Dare Bioscience, Inc. (DARE): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. dare-20260611 0001401914 FALSE 0001401914 2026-04-13 2026-04-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
How this was made
The 30-second read
Why it matters
The key incremental item for trading is Proposal 6: shareholder approval of an amendment to the 2022 Stock Incentive Plan that increases shares available for issuance by 1,500,000; other proposals include ratifying the auditor and approving the equity line’s potential future issuance.
Market read
This is primarily a dilution/compensation-governance update; it may move the stock modestly if the market is sensitive to equity overhang, but it does not introduce new clinical or financial catalysts.
What to watch
Traders should also consider the concurrent vote results (say-on-compensation frequency, equity line with Lincoln Park) as they can collectively shape dilution expectations.
Background
The filing is an SEC 8-K summarizing results from Daré Bioscience’s June 11, 2026 annual stockholder meeting, including director elections and multiple proposals tied to compensation and equity issuance.
Ticker impact
Daré Bioscience’s stockholders approved an amendment to its 2022 Stock Incentive Plan, increasing shares available by 1,500,000.
Likely modest, sentiment-driven impact; near-term trading may reflect dilution/overhang concerns rather than fundamentals.
This is a corporate governance/equity-plan approval with no new operating or financial guidance, but it can influence perceived dilution risk and future share issuance capacity.
Market effects
Limited sector read-through; equity-plan amendments are common among small/mid-cap biotechs.
None material beyond the single issuer.
None.
Counterpoint
The plan increase may simply be routine to support ongoing hiring/retention and does not necessarily imply near-term heavy issuance.
Key entities
- issuerDaré Bioscience, Inc.
Nasdaq-listed biotech company filing the 8-K with voting results and the approved 2022 Stock Incentive Plan amendment.
- counterpartyLincoln Park Capital Fund, LLC
Referenced in Proposal 5 regarding potential future issuance under an existing equity line.
- auditorHaskell & White LLP
Independent registered public accounting firm ratified for fiscal year ending Dec. 31, 2026.
